Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
AstraZeneca
Cerilliant
Argus Health
Mallinckrodt
Fuji
Farmers Insurance
Chinese Patent Office

Generated: May 26, 2018

DrugPatentWatch Database Preview

NATESTO Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Natesto patents expire, and what generic alternatives are available?

Natesto is a drug marketed by Aytu Bioscience Inc and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-seven patent family members in twenty-one countries.

The generic ingredient in NATESTO is testosterone. There are sixty-three drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for NATESTO
International Patents:27
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 61
Clinical Trials: 3
Formulation / Manufacturing:see details
DailyMed Link:NATESTO at DailyMed
Drug patent expirations by year for NATESTO
Pharmacology for NATESTO
Ingredient-typeAndrostanes
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for NATESTO

US Patents and Regulatory Information for NATESTO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for NATESTO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,579,280 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
2,014,073,618 ➤ Sign Up
9,238,072 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Harvard Business School
Mallinckrodt
Julphar
Fish and Richardson
Baxter
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.